Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 15/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303898 | 1.00 | SRD5A1 (0.39) | SRD5A1KDM4ECYP3A4THRBTSHR | |
| SCHEMBL16079969 | 0.87 | BRD4 (0.37) | SRD5A1MAPK1PIK3CD | |
| SCHEMBL10491068 | 0.85 | BRD4 (0.35) | SRD5A1MAPK1KMT2APIK3CD | |
| SCHEMBL2036879 | 0.80 | SRD5A1 (0.34) | SRD5A1KDM4ECYP3A4THRBTSHR | |
| SCHEMBL22753756 | 0.77 | KDM4E (0.33) | SRD5A1KDM4ECYP3A4THRBTSHR | |
| SCHEMBL10160264 | 0.76 | — | — | |
| SCHEMBL28410579 | 0.76 | ACE (0.33) | PIK3CD | |
| SCHEMBL2706865 | 0.76 | TSHR (0.37) | KDM4ETSHRKMT2ANPSR1PIK3CD | |
| SCHEMBL18366635 | 0.76 | PIK3CD (0.32) | MAPK1PIK3CD | |
| SCHEMBL10303445 | 0.76 | TSHR (0.37) | KDM4ETSHRKMT2ANPSR1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | 280 Bio, Inc (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2022106857-A1 | MALT-1 MODULATORS | Exscientia Limited (GB) | 2022-05-27 | — | — | WO | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SRD5A1 3125/4885KDM4E 2496/4885CYP3A4 1770/4885 |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | NRAS, KRAS, RAB8A | SRD5A1 821/4885KDM4E 4407/4885CYP3A4 753/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SRD5A1 3125/4885KDM4E 2496/4885CYP3A4 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.